FDA, India Act To Prevent Shipments Of Illegal Medicine From Entering U.S.
The U.S. Food and Drug Administration Feb. 18 announced that its first bilateral enforcement operation with the Government of India stopped approximately 500 shipments of illicit, and potentially dangerous, unapproved prescription drugs and combination medical devices from reaching American consumers.
The operation was conducted in January.
“With standards and regulations varying in each country, U.S. consumers face hazards when they order drugs and other FDA-regulated products from unauthorized foreign sources and receive them through the international mail system,” FDA commissioner Stephen M. Hahn said in a statement. “Consumers and physicians purchasing medicines cannot be assured the products they are receiving are legitimate, safe or effective if they are obtained from outside of the FDA-regulated pharmaceutical supply chain,” he said.
The FDA is committed to empowering patients and providing them choice, but also protecting them through collaboration with our international regulatory and law enforcement partners,” Hahn added. “It is vital that we aggressively stop illicit products from entering the country that may place patients’ health at risk, and we are pleased to call the Government of India a partner in this effort.”
Operation Broadsword targeted packages entering the U.S. through an International Mail Facility from Jan. 28 through Jan. 30, according to a news release.
Investigators from both governments examined more than 800 shipments, which identified approximately 50 different FDA-regulated products, including medications intended to treat and or mitigate serious diseases, such as various forms of cancer and HIV, it said.
Many of the shipments, which included opioid drugs products, had been transshipped through third-party countries to conceal their point of origin and avoid detection. Health risks are further compounded when products are sent through such third-party countries, which undermines protections afforded via regulated pharmaceutical supply chains, the FDA added.
In September 2019, a senior-level FDA delegation traveled to India for the purpose of strengthening bilateral engagement. A series of stakeholder meetings were held at the U.S. Embassy in New Delhi as well as with the government of India’s Central Board of Indirect Taxes and Customs, the Directorate of Revenue Intelligence, and the Central Drug Standard Control Organization in support of an ongoing bilateral initiative to combat public health and safety-based crime, the release said.
“A bilateral enforcement exercise like Operation Broadsword allows us to closely work with our U.S. counterparts so as to share best practices, develop intelligence, better target suspect consignments, consignors and other bad actors at both ends,” said Balesh Kumar, director general of the Directorate of Revenue Intelligence for the Government of India.
Each day across the U.S., nine IMFs receive mail from more than 180 countries, and it is part of the FDA’s mission to inspect, detect and intercept illegal products, including those that are unapproved, counterfeit and/or potentially dangerous, such as illicit opioid products, counterfeit prescription drugs, medical devices, over-the-counter products, and products labeled as dietary supplements that may contain harmful ingredients, the release said.
In fiscal year 2019, the FDA screened approximately 25,200 parcels, containing more than 41,000 products combined at all of its IMF facilities. The FDA detained more than 38,000 of those products, and expects to ultimately destroy more than 17,000 of those products as drugs subject to the FDA’s administrative destruction authority, it said.
“Such an exercise also has potential for long term capacity building. The Directorate of Revenue Intelligence is committed to fighting the menace of drugs and narcotics and international cooperation with agencies like the U.S. FDA can help us in our efforts towards this cause,” Kumar said.-IndiaWest